ERBB2 and colorectal carcinoma: Other promising agents which might play a role in the personalized management of CRC liver metastases in the future include BRAF inhibitors (e.g., combination trametinib/dabrafenib) for BRAF mutant CRC or dual anti-Her2 therapy (trastuzumab and lapatinib) for HER2-positive disease [30].